The global immunomodulators market attained a value of about USD 207.25 billion in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 5.8% to reach nearly USD 343.62 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America is a significant market for the global immunomodulatory industry because of the growing geriatric population in this region. Due to the surging incidence of chronic diseases like sclerosis, Crohn’s disease, ulcerative colitis in the United States, demand from end-users for immunomodulator-based treatment and the high therapy cost associated with the treatment of sclerosis are anticipated to drive revenue growth in this segment. Further, awareness among the masses and government initiatives are also boosting the immunomodulator industry. Europe, on the other hand, is expected to witness substantial growth backed by the increasing sales of immunosuppressant products in the region.
COVID-19 has shown its footprint across the globe, severely affecting many economies and industries due to lockdowns and several restrictions. However, coronavirus has positively affected the immunomodulator industry, owing to rise in the sales of products with respect to the emergency. Various pharmaceutical companies are trying to balance demand and supply to keep their sales flow smooth. These pharmaceutical companies are now trying to invest more in quality control, strengthen their research and development departments, and magnify supply chain management, which is expected to boost the market growth over the forecast period.
Immunomodulators are substances that are used to regulate or normalise the immunity system. It supports immune function by modifying, generally in a healthy way, the immune system’s response to a threat. They are directed to enhance the immune response against infectious diseases, tumours, primary or secondary immunodeficiency, and alterations in antibody transfer, among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major types of immunomodulators on the basis of product are:
The market can be broadly categorised on the basis of its applications into:
The EMR report looks into the regional markets of immunomodulators like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The key contributory factor in the growth of the global immunomodulators industry is the increasing incidence of chronic diseases, including asthma, allergic conditions, cancer, and multiple sclerosis. Further, some of the factors contributing to the growth of the immunomodulator industry include the prevailing cases of organ transplantation, increasing adoption of an early immunomodulator therapy for the Crohn’s disease treatment, rising awareness about inflammatory bowel diseases, growing autoimmune diseases, and increasing development of drug resistance, which is resulting in the rise of immunomodulators usage.
However, the market growth may hinder due to the presence of stringent regulatory approval procedures, along with the high cost of the therapy and the immunomodulator products. Further, adverse effects of immunomodulatory drugs, such as pain, inflammation, epilepsy, are likely to restrain the market growth during the forecast period.
The report presents a detailed analysis of the following key players in the global immunomodulators market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Product||
|Breakup by Applications||
|Breakup by Route of Administration||
|Breakup by End User||
|Breakup by Distribution Channel||
|Breakup by Region||
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Immunomodulators Market Overview
3.1 Global Immunomodulators Market Historical Value (2017-2023)
3.2 Global Immunomodulators Market Forecast Value (2024-2032)
4 Global Immunomodulators Market Landscape
4.1 Global Immunomodulators Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Immunomodulators Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Applications
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by End Users
5 Global Immunomodulators Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Immunomodulators Market Segmentation
6.1 Global Immunomodulators Market by Product
6.1.1 Market Overview
22.214.171.124 Calcineurin Inhibitors
6.2 Global Immunomodulators Market by Applications
6.2.1 Market Overview
6.2.3 Human Immunodeficiency Virus (HIV)
6.3 Global Immunomodulators Market by Route of Administration
6.3.1 Market Overview
6.4 Global Immunomodulators Market by End User
6.4.1 Market Overview
6.4.3 Specialty Centres
6.5 Global Immunomodulators Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Retail Pharmacy
6.5.4 Online Pharmacy
6.6 Global Immunomodulators Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Immunomodulators Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Immunomodulators Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Immunomodulators Market
9.1 Market Share by Country
10 Latin America Immunomodulators Market
10.1 Market Share by Country
11 Middle East and Africa Immunomodulators Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
17 Supplier Landscape
17.1 NPO Petrovax Pharm
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.2 ResoTher Pharma
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.3 InDex Pharmaceuticals Holding AB
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.5 Spring Bank Pharmaceuticals.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.6 Horizon Therapeutics plc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.7 Johnson & Johnson Services, Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.8 BioNTech SE
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.9 ZERIA Pharmaceutical Co., Ltd.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.10 Atox Bio.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.11 Takeda Pharmaceutical Company Limited
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.12 F. Hoffmann-La Roche Ltd.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.13 Amgen Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.14 Novartis AG
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.15 GlaxoSmithKline plc.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.16 Merck & Co., Inc.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.17 Pfizer Inc.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
18 Global Immunomodulators Market - Distribution Model (Additional Insight)
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
In 2023, the market attained a value of approximately USD 207.25 billion.
The market is projected to grow at a CAGR of 5.8% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach about USD 343.62 billion by 2032.
The market is being driven by the prevailing cases of organ transplantation that boosts the demand for immunomodulator drugs, growing geriatric population, and rising incidence of chronic conditions.
The key trends of the market include rapid technological advancements in the healthcare industry and the expanding applications of immunomodulators through novel combinations to treat multiple conditions.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The primary products of immunomodulators available in the market are immunosuppressants and immunostimulants.
The major applications of immunomodulators are oncology, respiratory, and HIV, among others.
The key players in the global immunomodulators market are F. Hoffmann-La Roche Ltd., Amgen, Inc., Abbott Laboratories, Novartis AG, and Biogen Inc., among others.
The global immunomodulators market attained an approximate value of USD 207.25 billion in 2023, driven by the rising prevalence of awareness among the masses regarding immunomodulators. Aided by the rising chronic diseases, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 5.8%. The market is projected to reach nearly USD 343.62 billion by 2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its products, the immunomodulators industry can be segmented into immunosuppressants and immunostimulants. On the basis of application, the market is categorised into oncology, respiratory, and HIV, among others. The major regional markets for immunomodulators are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include F. Hoffmann-La Roche Ltd., Amgen, Inc., Abbott Laboratories, Novartis AG, and Biogen Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.